PALB2 variants in hereditary and unselected finnish Prostate cancer cases

Journal of Negative Results in BioMedicine

Volumn 8, Issue 1, 2009, Pages

  Pakkanen, Sanna ^a   Wahlfors, Tiina ^a   Siltanen, Sanna ^a   Patrikainen, Mimmi ^a   Matikainen, Mika P ^b   Tammela, Teuvo L J ^b   Schleutker, Johanna ^a  

^a UNIVERSITY OF TAMPERE   (Finland)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 ASSOCIATED RING DOMAIN PROTEIN 1; BRCA2 PROTEIN; MITOMYCIN C; PROSTATE SPECIFIC ANTIGEN; MITOMYCIN; NUCLEAR PROTEIN; PALB2 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

ADULT; AGED; ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; FAMILIAL CANCER; FINLAND; GENE DELETION; GENE MUTATION; GENETIC VARIABILITY; GENOTYPE; GLEASON SCORE; HETEROZYGOTE DETECTION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; ONCOGENE; PALB2 GENE; PROSTATE CANCER; CELL PROLIFERATION; DNA DAMAGE; DRUG EFFECT; FAMILY; FEMALE; GENETICS; INHERITANCE; MIDDLE AGED; MUTATION; PEDIGREE; PROSTATE TUMOR; TUMOR CELL LINE;

ADULT; AGED; CELL LINE, TUMOR; CELL PROLIFERATION; DNA DAMAGE; DNA MUTATIONAL ANALYSIS; FAMILY; FEMALE; FINLAND; HUMANS; INHERITANCE PATTERNS; MALE; MIDDLE AGED; MITOMYCIN; MUTATION; NUCLEAR PROTEINS; PEDIGREE; PROSTATIC NEOPLASMS; TUMOR SUPPRESSOR PROTEINS;

EID: 74849119957     PISSN: None     EISSN: 14775751     Source Type: Journal    
DOI: 10.1186/1477-5751-8-12     Document Type: Article

References (28)

1. The prostate: an increasing medical problem. HB Carter DS Coffey, Prostate 1990 16 39 48 10.1002/pros.2990160105 1689482
2. Finnish Cancer Registry. Cancer incidence and mortality in Finland. Cancer Statistics 2007 http://www.cancerregistry.fi
3. Interpreting trends in prostate cancer incidence and mortality in the five Nordic countries. R Kvale A Auvinen HO Adami A Klint E Hernes B Moller E Pukkala HH Storm L Tryggvadottir S Tretli R Wahlqvist E Weiderpass F Bray, J Natl Cancer Inst 2007 99 1881 1887 10.1093/jnci/djm249 18073376
4. The complex genetic epidemiology of prostate cancer. DJ Schaid, Hum Mol Genet 2004 13 Spec No 1 103 21 10.1093/hmg/ddh072 14749351
5. A candidate prostate cancer susceptibility gene at chromosome 17p. SV Tavtigian J Simard DH Teng V Abtin M Baumgard A Beck NJ Camp AR Carillo Y Chen P Dayananth M Desrochers M Dumont JM Farnham D Frank C Frye S Ghaffari JS Gupte R Hu D Iliev T Janecki EN Kort KE Laity A Leavitt G Leblanc J McArthur-Morrison A Pederson B Penn KT Peterson JE Reid S Richards M Schroeder R Smith SC Snyder B Swedlund J Swensen A Thomas M Tranchant AM Woodland F Labrie MH Skolnick S Neuhausen J Rommens LA Cannon-Albright, Nat Genet 2001 27 172 180 10.1038/84808 11175785
6. Germline mutations in the ribonuclease L gene in families showing linkage with HPC1. J Carpten N Nupponen S Isaacs R Sood C Robbins J Xu M Faruque T Moses C Ewing E Gillanders P Hu P Bujnovszky I Makalowska A Baffoe-Bonnie D Faith J Smith D Stephan K Wiley M Brownstein D Gildea B Kelly R Jenkins G Hostetter M Matikainen J Schleutker K Klinger T Connors Y Xiang Z Wang A De Marzo N Papadopoulos OP Kallioniemi R Burk D Meyers H Gronberg P Meltzer R Silverman J Bailey-Wilson P Walsh W Isaacs J Trent, Nat Genet 2002 30 181 184 10.1038/ng823 11799394
7. Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. J Xu SL Zheng A Komiya JC Mychaleckyj SD Isaacs JJ Hu D Sterling EM Lange GA Hawkins A Turner CM Ewing DA Faith JR Johnson H Suzuki P Bujnovszky KE Wiley AM DeMarzo GS Bova B Chang MC Hall DL McCullough AW Partin VS Kassabian JD Carpten JE Bailey-Wilson JM Trent J Ohar ER Bleecker PC Walsh WB Isaacs DA Meyers, Nat Genet 2002 32 321 325 10.1038/ng994 12244320
8. ELAC2/HPC2 involvement in hereditary and sporadic prostate cancer. A Rokman T Ikonen N Mononen V Autio MP Matikainen PA Koivisto TL Tammela OP Kallioniemi J Schleutker, Cancer Res 2001 61 6038 6041 11507049 (Pubitemid 32762535)
9. Germline alterations of the RNASEL gene, a candidate HPC1 gene at 1q25, in patients and families with prostate cancer. A Rokman T Ikonen EH Seppala N Nupponen V Autio N Mononen J Bailey-Wilson J Trent J Carpten MP Matikainen PA Koivisto TL Tammela OP Kallioniemi J Schleutker, Am J Hum Genet 2002 70 1299 1304 10.1086/340450 11941539
10. Germ-line alterations in MSR1 gene and prostate cancer risk. EH Seppala T Ikonen V Autio A Rokman N Mononen MP Matikainen TL Tammela J Schleutker, Clin Cancer Res 2003 9 5252 5256 14614006
11. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. MC King JH Marks JB Mandell New York Breast Cancer Study Group, Science 2003 302 643 646 10.1126/science.1088759 14576434
12. BRCA2 mutation in Icelandic prostate cancer patients. S Sigurdsson S Thorlacius J Tomasson L Tryggvadottir K Benediktsdottir JE Eyfjord E Jonsson, J Mol Med 1997 75 758 761 10.1007/s001090050162 9383000
13. BRCA1 and BRCA2 pathways and the risk of cancers other than breast or ovarian. B Friedenson, Med Gen Med 2005 7 60
14. Prostate cancer progression and survival in BRCA2 mutation carriers. L Tryggvadottir L Vidarsdottir T Thorgeirsson JG Jonasson EJ Olafsdottir GH Olafsdottir T Rafnar S Thorlacius E Jonsson JE Eyfjord H Tulinius, J Natl Cancer Inst 2007 99 929 935 10.1093/jnci/djm005 17565157
15. A review of targeted screening for prostate cancer: introducing the IMPACT study. AV Mitra EK Bancroft RA Eeles IMPACT Steering Committee Collaborators, BJU Int 2007 99 1350 1355 10.1111/j.1464-410X.2007.06759.x 17419707
16. BRCA1 and BRCA2 mutations have no major role in predisposition to prostate cancer in Finland. T Ikonen MP Matikainen K Syrjakoski N Mononen PA Koivisto A Rokman EH Seppala OP Kallioniemi TL Tammela J Schleutker, J Med Genet 2003 40 98 10.1136/jmg.40.8.e98 12920090
17. Risk of cancer in BRCA1 and BRCA2 mutation-positive and-negative breast cancer families (Finland). H Eerola E Pukkala S Pyrhonen C Blomqvist R Sankila H Nevanlinna, Cancer Causes Control 2001 12 739 746 10.1023/A:1011272919982 11562114 (Pubitemid 32803500)
18. CHEK2 variants associate with hereditary prostate cancer. EH Seppala T Ikonen N Mononen V Autio A Rokman MP Matikainen TL Tammela J Schleutker, Br J Cancer 2003 89 1966 1970 10.1038/sj.bjc.6601425 14612911
19. Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. B Xia Q Sheng K Nakanishi A Ohashi J Wu N Christ X Liu M Jasin FJ Couch DM Livingston, Mol Cell 2006 22 719 729 10.1016/j.molcel.2006.05.022 16793542
20. PALB2 links BRCA1 and BRCA2 in the DNA-damage response. F Zhang J Ma J Wu L Ye H Cai B Xia X Yu, Curr Biol 2009 19 524 529 10.1016/j.cub.2009.02.018 19268590
21. A recurrent mutation in PALB2 in Finnish cancer families. H Erkko B Xia J Nikkila J Schleutker K Syrjakoski A Mannermaa A Kallioniemi K Pylkas SM Karppinen K Rapakko A Miron Q Sheng G Li H Mattila DW Bell DA Haber M Grip M Reiman A Jukkola-Vuorinen A Mustonen J Kere LA Aaltonen VM Kosma V Kataja Y Soini RI Drapkin DM Livingston R Winqvist, Nature 2007 446 316 319 10.1038/nature05609 17287723
22. Detection of subclinical cancers by prostate-specific antigen screening in asymptomatic men from high-risk prostate cancer families. MP Matikainen J Schleutker P Morsky OP Kallioniemi TL Tammela, Clin Cancer Res 1999 5 1275 1279 10389909
23. PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. N Rahman S Seal D Thompson P Kelly A Renwick A Elliott S Reid K Spanova R Barfoot T Chagtai H Jayatilake L McGuffog S Hanks DG Evans D Eccles Breast Cancer Susceptibility Collaboration (UK) DF Easton MR Stratton, Nat Genet 2007 39 165 167 10.1038/ng1959 17200668
24. Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene. SM Edwards Z Kote-Jarai J Meitz R Hamoudi Q Hope P Osin R Jackson C Southgate R Singh A Falconer DP Dearnaley A Ardern-Jones A Murkin A Dowe J Kelly S Williams R Oram M Stevens DM Teare BA Ponder SA Gayther DF Easton RA Eeles Cancer Research UK/Bristish Prostate Group UK Familial Prostate Cancer Study Collaborators British Association of Urological Surgeons Section of Oncology, Am J Hum Genet 2003 72 1 12 10.1086/345310 12474142
25. Analysis of FANCB and FANCN/PALB2 fanconi anemia genes in BRCA1/2-negative Spanish breast cancer families. MJ García V Fernndez A Osorio A Barroso G Llort C Lzaro I Blanco T Caldés M de la Hoya Y Ramán T Cajal C Alonso MI Tejada C San Romn L Robles-Díaz M Urioste J Benítez, Breast Cancer Res Treat 2009 113 545 51 10.1007/s10549-008-9945-0 18302019
26. Analysis of the gene coding for the BRCA2-Interacting protein PALB2 in hereditary prostate cancer. M Tischkowitz N Sabbaghian AM Ray EM Lange WD Foulkes KA Cooney, Prostate 2008 68 675 678 10.1002/pros.20729 18288683
27. Analysis of PALB2/FANCN-associated breast cancer families. M Tischkowitz B Xia N Sabbaghian JS Reis-Filho N Hamel G Li EH van Beers L Li T Khalil LA Quenneville A Omeroglu A Poll P Lepage N Wong PM Nederlof A Ashworth PN Tonin SA Narod DM Livingston WD Foulkes, PNAS 2007 104 6788 6793 10.1073/pnas.0701724104 17420451
28. Disease gene mapping in isolated human populations: the example of Finland. A de la Chapelle, J Med Genet 1993 30 857 865 10.1136/jmg.30.10.857 8230163